Current approaches to overcome resistance are focused on combining PARP inhibition with other inhibitors of the DNA damage response, immune-checkpoint inhibition or targeted therapies. Targeting the acquired vulnerabilities of PARP inhibitor-resistant tumours might selectively kill unresponsive cancer cells. Pr...
Cancer DNA repair mechanisms, and resistance to chemotherapy. J. Natl. Cancer Inst. 93, 1434-1436.Fojo, T. (2001). Cancer, DNA repair mechanisms, and resistance to chemotherapy. Journal of the National Cancer Institute, 93 , 1434–1436. View Article...
Immune checkpoint inhibitors (ICIs) have altered the treatment paradigm across a range of tumour types, including gastro-oesophageal cancers. For patients with any cancer type who respond, ICIs can confer long-term disease control and significantly improve survival and quality of life, but for patien...
Drug resistance represents a significant obstacle in cancer treatment, underscoring the need for the discovery of novel therapeutic targets. Ubiquitin-specific proteases (USPs), a subclass of deubiquitinating enzymes, play a pivotal role in protein deubi
PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications The abundant nuclear enzyme poly(ADP-ribose)polymerase-1 (PARP-1) represents an important novel target in cancer therapy. PARP-1 is essential to the repair... Y Drew,R Plummer - 《Dr...
The summery of miRNA-mediated resistance mechanisms (a) Abnormal transmembrane transport; (b) Alterations of DNA damage repair; (c) Dysregulation of cancer-associated signal pathway; (d) Epigenetic modification Full size image Based on the abovementioned findings, we retrieved phase I/II clinical tr...
PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 blockade therapy has been trialed in a broad range of malignancies and achieved clini
As such, the concept of targeting DNA repair has been successfully developed in the last decade to a bona fide therapeutic strategy with poly (ADP-ribose) polymerase inhibitors (PARPi) to treat DNA repair deficient breast, ovarian, pancreatic, and prostate cancers[3-9]. These successes have ...
DNA damage repair, apoptosis, characteristics of cancer stem cells, immune evasion, and other crucial biological functions. Additionally, the review highlights the potential clinical significance of USP inhibitors as a means to counter drug resistance in cancer treatment. By inhibiting particular USP, ...
for clinical trials in tandem with radiation therapies. In those treatments, radiation damages cancer cell DNA, and the thought was that inhibiting DNA-PKcs would limit cell repair. But, DNA-PKcs inhibitors don't work well in that context, as cancer cells have other ways to repair themselves....